Domantis First To Win UK Innovation In Drug Discovery & Development Award

Domantis is the first winner of the UK Innovation in Drug Discovery & Development Award, one of three new BioEntrepreneur Awards sponsored by London First and UK Trade & Investment.

The award recognises Domantis’ contribution to the UK’s dominant position in the development of innovative medicine.

Executive VP and CSO Dr. Ian Tomlinson said, "I am delighted to receive this award which highlights Domantis’ pioneering approach to developing novel therapeutics based on human Domain Antibodies.”

“Domantis is currently building a rich pipeline of novel dAb medicines to combat disorders such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis (RA) and cancer.”

The two other finalists were Powdermed and Spirogen.

Domantis Limited

Domantis Limited
Drug discovery platform

Website
www.gsk.com

Downloads

DownloadFull Press Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.